gtm_report

6.2 Channels

Slide 1 - Cover (LAVisions layout)layout: title_hero · 16:9
Tola
Go to Market
How we reach every shelf and inbox.
Demand-Side Strategy Retail-led, proof-anchored, word-of-mouth-amplified
Channel 1 Sephora 450-door retail footprint and front-of-aisle display
Channel 2 tola.co direct with subscription and bundle attach
Channel 3 US specialty and dermatology-led press and word of mouth
Demand Funnel Sephora trial to tola.co reorder to bundle to subscription
Unit Economics CAC $87, 41% reorder within 90 days, LTV $358, 4.0x LTV to CAC
Demand Side Retail reach, direct retention, press credibility 450 Sephora doors acquire the customer, tola.co and specialty retail keep her
Sephora rollout 450 doors live by Q3 2026 with front-of-aisle hero-set display
tola.co direct Reorders at roughly double the Sephora wholesale margin
US specialty Credo, Bluemercury, and Goop for premium-clinical credibility
Bundles and subscription Starter Set $165 and Ritual Set $245, subscription from Q3 2026
Founder-led press Dermatology advisory and clinical proof drive earned media
Retail reach, direct margin, and clinical proof compound the customer value The 50-door Sephora pilot sold 89% of stock against a 65 to 70% prestige benchmark, contractually triggering the 450-door rollout for 2026 (Q4 2025 pilot data).
Supply Side Cooperative sourcing, US formulation, contract manufacturing Named farmer cooperatives plus Brooklyn formulation plus contract fill
Farmer cooperatives Eudafano Namibia, Baobab Senegal, Cape Rooibos Direct, Kenyan moringa
Multi-year contracts Locked pricing at 28% above commodity across growing seasons
Brooklyn formulation Dr Patel's lab owns molecular characterisation and IRB study design
Contract manufacturing US contract fill scales unit volume without a capital plant
Clinical labs Third-party IRB labs run the double-blind efficacy studies
Cooperative provenance, in-house science, and contract scale equal a defensible supply moat Direct sourcing from three farmer cooperatives at 28% above commodity pricing creates a supply moat that takes multiple growing seasons to copy.
Supply-Side Strategy Cooperative-sourced, US-formulated, contract-manufactured
Channel 1 Named farmer cooperatives on multi-year contracts
Channel 2 In-house Brooklyn formulation and IRB study design
Channel 3 US contract manufacturing for scale fill
Key Metrics Cooperative capacity, active concentration, batch consistency, study endpoints
Delivery Strategy Cooperatives secure the actives, the lab owns the proof, contract fill carries the volume
Customer Personas Three buyers, three trigger moments, one clinical routine
The Clinical Convert
Demographics Age 28-45, US metro, high disposable income, INCI-literate Pain Points Owns every validated active already and has nothing new to try Discovery Sephora aisle, dermatology press, r/SkincareAddiction, clinical creators on TikTok Values Published proof, printed dose, single-active discipline Willingness to Pay $150 to $350 per year
The Dermatologist-Referred
Demographics Age 35-60, treating a barrier or sensitivity concern, clinician-guided Pain Points Needs efficacy she can trust that layers with prescription products Discovery Dermatology office, Bluemercury, Dr Wexler-tier practitioner referral Values IRB studies, tolerability, stack-compatibility with retinoids and acids Willingness to Pay $200 to $400 per year
The Prestige Gifter
Demographics Age 30-55, gifting or trialling through a set, brand-curious Pain Points Wants a considered premium gift that signals science, not hype Discovery Sephora gifting display, Goop, Selfridges, editorial gift guides Values Restrained packaging, bundle value, provenance story Willingness to Pay $165 to $245 per set
Channels & PartnershipsDirect retail, indirect specialty, community word of mouth
DirectSephora 450 doors and tola.co direct commerce
IndirectCredo, Bluemercury, Goop, and international partners of record
CommunityDermatology press, beauty editorial, and founder-led media
Channel StrategySephora and direct 65%, specialty and international 25%, community 10% in 2026
Strategic PartnershipsSephora US and Middle East, Selfridges UK, Lane Crawford HK, farmer cooperatives, Dr Wexler dermatology advisory
KPIs & Business Model 89% pilot sell-through, 41% reorder, first profit in 2029
Growth KPIs
Revenue Target $0.43M revenue 2026 to $13.75M by 2030
Sell-Through 89% Sephora pilot sell-through, 450 doors by Q3 2026
Reorder Rate 41% reorder within 90 days
Unit Economics
CAC $87 blended, rising to $110 by 2030
LTV $358 over 20 months
LTV : CAC Ratio 4.0x LTV to CAC
Payback Period Under 12 months
Revenue Model Wholesale plus DTC plus subscription
Pricing $42 to $94 per product, sets $165 to $245
Gross Margin 70% by 2029, 77% at scale
Break-Even First operating profit in 2029
Key Takeaway 89% Sephora sell-through triggered the 450-door rollout, and the customer reorders at 41%
Customer Acquisition Cost $87
Lifetime Value $358
LTV : CAC Ratio 4.0 : 1
Year 1 Projection 450 Sephora doors live by Q3 2026 plus tola.co direct, with 41% of customers reordering within 90 days and the subscription option launching Q3 2026